Valuation: Cerus Corporation

Market Cap 585M 514M 474M 443M 830M 55.17B 848M 5.69B 2.2B 27.23B 2.2B 2.15B 94.6B P/E 2026 *
-87.6x
P/E 2027 * -877x
Enterprise Value 585M 514M 474M 443M 830M 55.17B 848M 5.69B 2.2B 27.23B 2.2B 2.15B 94.6B EV / Sales 2026 *
2.46x
EV / Sales 2027 * 2.25x
Free-Float
96.59%
Yield 2026 *
-
Yield 2027 * -
1 day+2.10%
1 week+8.15%
Current month-3.95%
1 month+6.96%
3 months+59.56%
6 months+43.84%
Current year+41.75%
1 week 2.52
Extreme 2.52
3
1 month 2.41
Extreme 2.41
3.13
Current year 1.62
Extreme 1.62
3.15
1 year 1.15
Extreme 1.15
3.15
3 years 1.12
Extreme 1.12
3.15
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 59 2011-04-20
Chief Tech/Sci/R&D Officer 82 2015-06-30
Director of Finance/CFO 54 2009-05-03
Director TitleAgeSince
Chairman 59 2026-03-15
Director/Board Member 72 2014-03-23
Director/Board Member 66 2018-10-08
Date Insider Type Main position Quantity % Market Cap.
Jun. 08Sell

Director

-20,454 0.0102%
Jun. 01Free

Director

60,000 0.0299%
Jun. 01Free

Director

60,000 0.0299%
Change 5-day change 1-year change 3-year change Capi.($)
+2.10%+8.15%+114.71%+23.73% 585M
+5.25%+8.09%-14.78%+12.08% 128B
-0.65%+1.20%+3.41%-8.11% 12.77B
+1.30%+10.51%+42.91%+109.94% 8.48B
-3.88%-6.41%-50.34%-72.89% 3.79B
-0.38%-0.97%+17.98%+37.20% 2.52B
-9.06%+4.50%+229.48%+156.69% 1.55B
-8.75%-13.25%-26.46%-23.39% 1.53B
-2.80%-3.48%-1.78%-22.72% 1.53B
Average -1.87%+0.61%+35.01%+23.61% 17.81B
Weighted average by Cap. +3.91%+6.82%-7.75%+14.81%

Financials

2026 *2027 *
Net sales 238M 209M 193M 180M 338M 22.45B 345M 2.32B 897M 11.08B 894M 875M 38.5B 260M 228M 210M 197M 369M 24.5B 377M 2.53B 979M 12.09B 976M 954M 42.01B
Net income -6.24M -5.48M -5.05M -4.73M -8.85M -588M -9.04M -60.66M -23.49M -290M -23.42M -22.91M -1.01B -479K -421K -388K -363K -680K -45.2M -695K -4.66M -1.81M -22.31M -1.8M -1.76M -77.5M
Net Debt - -
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
26-06-26 $2.920 +2.10% 7,434,823
26-06-25 $2.860 +8.33% 4,026,692
26-06-24 $2.640 +1.93% 2,784,607
26-06-23 $2.590 -0.38% 2,687,593
26-06-22 $2.600 -3.70% 1,935,385
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.920USD
Average target price
4.667USD
Spread / Average Target
+59.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock